Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.6K citations

Mixed-phenotype Acute Leukemia, Pathology, Acute Leukemia +18

A small molecule–kinase interaction map for clinical kinase inhibitors

Miles A. Fabian, William Biggs, Daniel K. Treiber et al. · Nature Biotechnology · 2005 · 1.9K citations · Full text

Molecular Docking, Drug Target, Clinical Kinase Inhibitors +4

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

Jeffrey E. Rubnitz, Hiroto Inaba, Gary V. Dahl et al. · The Lancet Oncology · 2010 · 571 citations

Hematological Malignancy, Pediatric Hematology, Medicine +8

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

Farhad Ravandi, Jörge E. Cortes, Daniel M. Jones et al. · Journal of Clinical Oncology · 2010 · 355 citations · Full text

Hematological Malignancy, Oncology, Phase I/ii Study +13

Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia

Weiguo Zhang, Marina Konopleva, Yue-Xi Shi et al. · JNCI Journal of the National Cancer Institute · 2008 · 338 citations · Full text